Research Notes

Stay informed with the most recent market and company research insights.

A man sitting at a table with a glass of orange juice.

Research Notes

Major clinical trials to read out soon – key inflection point

Opthea
3:27pm
February 3, 2025
Opthea (OPT) is a biopharmaceutical company developing a potential treatment for wet age-related macular degeneration (wet AMD), a serious eye condition effecting 3.1m people in the US and Europe. The existing market for current treatments is estimated by management at US$15bn. Two major clinical trials are due to read out within the next 6 months and if successful, approval in the US is anticipated in 2HCY26. Consensus has a target price of A$2.07 compared with the current price of $1.07. We have prepared a brief note outlining the upcoming clinical trials and timelines noting the near-term catalysts are binary and appropriate for investors with a higher risk profile.

International Spotlight

General Motors Company
3:27pm
February 3, 2025
General Motors Company (GM-US), headquartered in Detroit, is a global automotive company known for brands like Chevrolet and Cadillac, offering a diverse portfolio of vehicles. A market leader with considerable scale, GM has global operations and employs over 165,000 staff worldwide.

2Q beat- sales mixed, but growth drivers remain intact

ResMed Inc
3:27pm
February 3, 2025
2Q results were above expectations, with double-digit top and bottom line growth, expanding margins and strong cash flow. The Americans posted strong, above market growth, with product segments benefiting from new patient set-ups/new releases and market leading cloud-connected device platforms, while ROW tracked the market and residential care software sales slowed, but inked double-digit profit gains. Despite a 30bp FX headwind, GPM surprised to the upside (yet again), with FY25 still targeting 59-60%, but 2HFY25 expected to be above 1HFY25 (59.2%). While sales diverged, we continue to view RMD as well positioned to benefit from growing sleep disorder awareness around trends in consumables and weight loss drugs. FY25-27 earnings increase up to 1.1%, with our target price rising to $43.60. Add.

A big opportunity and executing well

Findi
3:27pm
January 31, 2025
Findi (FND) is an ASX-listed fintech that operates in India’s large and fast-growing market. It has ~215k ATM/payment locations and processes >1 billion transactions per year. FND operates two key businesses: 1) an ATM solutions business, which deploys and manages ATMs through both Brown Label (BLA) and White Label ATM (WLA) agreements; and 2) a ‘Digital’ payments business (Findipay + BankIT), focused on dynamic payments and digital banking. The attraction of the FND story, in our view, is its established BLA operations, which give it a solid foothold in the sizeable Indian ATM/payments market. Furthermore, the areas management is targeting for future expansion (WLA and Digital) are far less capital intensive than FND’s traditional BLA operations, which should facilitate increasing returns and cashflow. We initiate coverage on FND with an ADD rating, with the stock trading at a ~40% discount to our A$7.17 blended valuation.

FY25’s 15% PBT growth guidance is looking tougher

Judo Capital Holdings
3:27pm
January 31, 2025
Monthly data that APRA releases on the domestic assets and liabilities of authorised deposit-taking institutions indicates JDO’s loan and deposit growth in 1H25 was slower than what we had expected for JDO to achieve its 15% PBT growth guidance for FY25. We’ve adjusted our forecasts downwards which had a valuation impact, but our 12 month target price has lifted upwards as we move closer in time to the strong growth in earnings that JDO is expected to generate. HOLD, $1.96 target price.

Steady progress although US growth still lumpy

ImpediMed
3:27pm
January 31, 2025
IPD posted its 2Q25 cash flow report which demonstrated solid sales growth and showed the cost base is under control. The US installed base growth was disappointingly below our forecast, although the pipeline of opportunities suggest subsequent quarters should see a meaningful step up in sales. Reimbursement coverage has increased to 75% of the US population which we think will move to over 90% in the next few quarters. We have revised our forecasts down to reflect the lower unit growth and as a result our valuation has reduced to A$0.17 (was A$0.19). Speculative Buy recommendation has been maintained.

Buying windows opening up

Sandfire Resources
3:27pm
January 31, 2025
2Q25 production and earnings were slightly below market expectations. SFR’s steady net debt reduction toward net cash during FY26 (our forecast) is pleasing, with consistent mine production at higher rates also a highlight. We like SFR’s methodical approach in unlocking incremental equity value, primarily via mine-plan optimisation and life extension. We now apply a small premium when deriving our upgraded target of $10.55ps. SFR remains a Hold, but better value buying windows are emerging on volatility.

A good house in a good neighbourhood

Digico Infrastructure REIT
3:27pm
January 30, 2025
DigiCo Infrastructure REIT (DGT) is a diversified owner, operator and developer of data centres, with a portfolio of 13 assets across Australia and North America. The stabilised leased assets (North America) underpin income, while the marquee value-add asset (SYD1) is a high-quality property with significant expansion potential. We see the existing portfolio underpinning the current share price, with the expansion / development potential the key source of future outperformance. The business has a slew of potential catalysts, centred on index inclusion (Mar-25) and the potential lease up of expansion space across the existing portfolio. We initiate coverage with an ADD recommendation and $5.60/share target price.

2Q25: From 6-7’s to 11’s

BETR Entertainment
3:27pm
January 30, 2025
BlueBet Holdings (BBT) posted another strong quarterly result today, coming in slightly ahead of our estimates. The company achieved an EBITDA positive half earlier than expected, driven by accelerated synergy gains and solid trading performance. Since the merger, betr margins have risen from 6-7% (before) to 11%, highlighting the success of the merger and the strength of its operating platform and promotional engine in reactivating dormant accounts. Our 12-month price target increases to $0.43 (previously $0.36). In 2Q25, BBT's cash active clients grew 20% sequentially, exceeding our expectations and reaching 144,697 by the end of the period (MorgansF: 12.5% growth). Turnover hit $357m, 2% above our estimates, while gross win reached $52.2m at a 14.6% margin (MorgansF: $50m). This translated to a strong net win margin of 11% (MorgansF: 10.2%). Encouragingly, BBT reports that 2Q25 trading momentum has carried into 3Q25. We expect a statutory benefit in 1H25 following the US exit, though some costs from the wind-down will offset this. The company reaffirmed its confidence in achieving over 10% market share through both organic and inorganic growth. BBT will release its interim result on 27 February 2025. We have taken our forecast FY25 EBITDA up from $4.2m to $4.9m.

Pivotal period for the USA

Credit Corp
3:27pm
January 30, 2025
CCP’s 1H25 NPAT of A$44.1m, +32% on pcp, was inline. Guidance was reaffirmed. Divisional composition was largely in-line, with the USA slightly below expectations (offset by Lending slightly ahead). USA was +16% on pcp, however -15% HOH. USA execution is pivotal in FY25 to prove up the ability of the division to deliver sustainable growth for CCP. Management’s commentary on operational performance was incrementally positive and purchasing guidance is sound; however a flow through to earnings from 2H25 is required for market confidence. Backing management’s execution in delivering on USA divisional growth expectations over FY25/26 is needed. We think the valuation point (~11.5x FY25PE) provides enough upside and risk/reward to do so. Add maintained.

News & Insights

Michael Knox outlines the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and his own analysis for Australia.

Today, I’m presenting the first page of my updated presentation, which focuses on GDP growth and inflation expectations for major economies. Before diving into that, I want to clarify a point about U.S. trade negotiations that has confused some media outlets.

In the previous Trump Administration ,there was single trade negotiator, Robert Lighthizer, held a cabinet position with the rank of Ambassador. This time, to expedite negotiations and give them more weight, Trump has appointed two additional cabinet-level officials to handle trade talks with different regions. For Asian economies, Scott Bessent and Ambassador Jamison Greer, who succeeded Lighthizer and previously served on the White House staff, are managing negotiations, including those with China. For Europe, Howard Lutnick, the Commerce Secretary, and Ambassador Greer are negotiating with the European Trade Representative. When the EU representative visits Washington, D.C., they meet with Lutnick and Greer, while Chinese or Japanese representatives engage with Bessent and Greer.

In my presentation today, I’m outlining the economic outlook for growth and inflation in the U.S., the Euro area, China, India, and Australia, drawing data from the International Monetary Fund, the Congressional Budget Office, European sources, and my own analysis for Australia.

For the U.S., the best-case scenario is a soft landing, with growth slowing but remaining positive at 1.3% this year and rising to 1.7% next year. This slowdown allows the Federal Reserve to continue cutting interest rates, leading to a decline in the U.S. dollar. This in turn ,triggers a recovery in commodity prices. These prices have stabilized and are now trending upward, with an expected acceleration as the dollar weakens.

U.S. headline inflation is projected to be just below 3% next year, with higher figures this year driven by tariff effects.



Global Economic Perspective

In the Euro area, growth is accelerating slightly, from just under 1% this year to 1.2% next year, with inflation expected to hit the 2% target this year and dip to 1.9% next year.

China’s GDP growth is forecast  at 4% for both this year and next, a step down from previous 5% rates, reflecting a significant slump in domestic demand and very low inflation  Chinese Inflation is only  :   0.2% last year, 0.4% this year, and 0.9% next year.  Despite a massive fiscal push, with a budget deficit around 8% of GDP, China’s debt-to-GDP ratio is rising faster than the U.S.. Yet this is  yielding more modest  domestic growth.

India, on the other hand, continues to outperform, with 6.5% GDP growth last year, 6.2% this year, and  6.3%  next year, surpassing earlier projections.

Read more
In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia.

Positive earnings surprise

In our International Reporting Season Review, we provide an overview of the March 2025 quarterly results season for companies in the Americas, Europe and Asia. For all the volatility in markets caused by US trade policy, the results were positive. For all the 187 high profile and blue-chip companies in our International Watchlist, the median EPS beat vs consensus was 3.2%, nearly twice that recorded in the December quarter (1.8%). 37% of companies exceeded consensus EPS expectations by more than 5% and only 9% missed by more than 5%. Communication Services was the most positive sector, led by Magnificent 7 companies Alphabet and Meta Platforms. The median EPS beat in that sector was 13%. Consumer Discretionary was the biggest disappointment (though only a mild one) with EPS falling 0.6% short of analyst estimates on a median basis.

Alphabet and Meta among the best performers

Across our Watchlist, some of the best performing stocks in terms of EPS beats were Alphabet, Boeing, Uniqlo-owner Fast Retailing, Meta Platforms, Newmont and The Walt Disney Company. Notable misses came from insurance broker Aon, BP, PepsiCo, Starbucks, Tesla and UnitedHealth. The latter saw by far the worst share price performance over reporting season, its earnings weakness compounded by the resignation of its CEO and the launch of a fraud investigation by the Department of Justice. British luxury fashion label Burberry had the best performing share price as it gains traction in its turnaround plan.

Tariffs were the main talking point (of course)

The timing of President Trump’s ‘Liberation Day’ on 2 April, just before the March quarter results started rolling in, guaranteed that US tariffs would be the main talking point throughout reporting season. Most companies took the line that higher tariffs presented a material risk to global growth and inflation. The rapidly shifting sands of US trade policy mean the impact of tariffs is highly uncertain. This didn’t stop many companies from trying to estimate the impact on their profits. This ranged from the very precise ($850m said RTX) to the extremely vague (‘a few hundred million dollars’ hazarded Abbott Laboratories). The rehabilitation of AI as a systemic driver of long-term value was a key theme of reporting season, with many companies reporting what Palantir Technologies described as an ‘unstoppable whirlwind of demand’ and others indicating an increase in planned AI investment. The deterioration in consumer confidence was another key talking point, though most companies could only express concern about a possible future softening in demand rather than any actual evidence of a hit to sales.

Our International Focus List continues to outperform

In this report, we also report on the performance of the Morgans International Focus List, which is now up 25.3% since inception last year, outperforming the benchmark S&P 500 by 20.4%.


Morgans clients receive exclusive insights such as access to our latest International Reporting Season article.

Contact us today to begin your journey with Morgans.

      
Contact us
      
      
Find an adviser
      
Read more
The U.S. and China, through negotiations led by the Chinese Deputy Premier and U.S. Treasury Secretary Scott Bessent, agreed to a 90-day tariff reduction from over 125% to 30% and 10% respectively

US and Chinese actions had led to an unintended embargo of trade between the world’s two largest economies.

In recent days there has been discussion of the temporary “cease fire” in the tariff war between the US and China.

The situation was that both countries had levied tariffs on each other more than 125%. This had led to a mutual embargo of trade between the two world is two largest economies. Then as a result of negotiation between the Deputy Premier of China and US Treasury Secretary Scott Bessent both China and the US agreed to a 90 day pause in “hostilities” where both sides agreed to reduce the US tariff on the China to 30 percent and the Chinese tariff on the US to 10%.

Some suggested that this meant that “China had won” others suggested that the “US had won.” To us this really suggests that both parties were playing in a different game. The was a game in which both sides had won.

To understand why this is the case we must understand a little of the theory of this type of competition. Economists usually use discuss competition in terms of markets where millions of people are involved. In such a case we find a solution by finding the intersection of supply and demand which model the exchange between vast numbers of people.

But here we are ware talking of a competition where only two parties are involved.

When exceedingly small numbers like this are involved, we find the solution to the competition by what is called “Game Theory.”

In this game there are only two players. One is called China, and the other is called the US. Game theory teaches us that are there three different types of games. The first is a zero-sum game. In this game there two sides are competing over a fixed amount of product. Again, this is called " A zero sum game “. Either one party gets a bigger share of the total sum at stake and the other side gets less. This zero-sum game is how most of the Media views the competition between the US and China.

A second form is a decreasing sum game. An example of this is a war. Some of the total amount that is fought over is destroyed in the process. Usually both sides will wind up worse than when they started.

Then there is a third form. This form is called an ‘increasing sum game.’ This is where both sides cooperate so that the total sum in the game grows because of this cooperation. We think that what happened in the US and China negotiation was an increasing sum game.

As Scott Bessent said at the Saudi Investment Forum in Riyadh soon after the agreement was signed, “both sides came with a clear agenda with shared interests and great mutual respect.”

He said, “after the weekend, we now have a mechanism to avoid escalation like we had before. We both agreed to bring the tariff levels down by 115% which I think is very productive because where we were with 145% and 125% was an unintended embargo. That is not healthy for the two largest economies in the world.”

He went on, “when President Trump began the tariff program, we had a plan, we had a process. What we did not have with the Chinese was a mechanism. The Vice Premier and I now call this the ‘Geneva mechanism’”.

Both sides cooperated to make both sides better off. Bessent added “what we do not want, and both sides agreed, is a generalised decoupling between the two largest economies in the world. What we want is the US to decouple in strategic industries, medicine, semiconductors, other strategic areas. As to other countries; we have had very productive discussions with Japan, South Korea, Indonesia, Taiwan, Thailand. Europe may have collective action problems with the French wanting one thing and the Italians wanting a different thing. but I am confident that with Europe, we will arrive at a satisfactory conclusion.

We have a very good framework. I think we can proceed from here.”

What we think we can see here is that the United States and China have cooperated to both become better off. This is what we call an increasing sum game.

They will continue their negotiation using that approach. This will do much to allay the concerns that so many had about the effect of these new tariffs.

Read more